Key result
Butorphanol protected human AC16 cardiomyocytes against OGD/R-induced apoptosis by activating the PI3K/Akt/FoxO and HIF-1α/VEGF pathways and inactivating the MAPK pathway.
Why the study?
Ischemic heart disease mortality is linked to cardiomyocyte apoptosis, and butorphanol has potential cardioprotective function, but its role and mechanism in OGD/R-induced apoptosis remain to be explored.
Does butorphanol prevent OGD/R-induced apoptosis in human cardiomyocyte AC16 cells?
Does butorphanol prevent OGD/R-induced apoptosis in human cardiomyocyte AC16 cells?
Butorphanol protects human cardiomyocytes against ischemia/reperfusion-like injury in vitro by modulating multiple signaling pathways, suggesting potential cardioprotective effects.
Answers are grounded in this paper and cite their sources.
Butorphanol's effects on cardiomyocyte apoptosis remain preclinical; leaves open clinical translation in ischemic heart disease.
Ischemic heart disease is the leading cause of cardiovascular mortality, which is related to cardiac myocyte apoptosis. Butorphanol is an opioid receptor agonist with potential cardioprotective function. The purpose of this work is to explore the function and mechanism of butorphanol in oxygen and glucose deprivation/reperfusion (OGD/R)-induced cardiomyocyte apoptosis. The overlapping targets of ischemic heart disease and butorphanol were analyzed according to GeneCards, ParmMapper, Cytoscape, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Human cardiomyocyte AC16 cells were incubated with butorphanol and then stimulated with OGD/R. Cell injury was investigated by Cell Counting Kit-8, lactate dehydrogenase (LDH) assay kit, TUNEL staining, caspase-3 activity assay kit, and Western blotting. The proteins in signaling pathways were measured using Western blotting. A total of 93 overlapping targets of ischemic heart disease and butorphanol were obtained. Pathway analysis exhibited that these targets might be involved in multiple signaling pathways. Butorphanol alone showed little cytotoxicity to cardiomyocytes, and it protected against OGD/R-induced viability inhibition, LDH release, cell apoptosis, and increase of caspase-3 activity and expression levels of cleaved caspase-3 and Bim. Butorphanol promoted the activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/forkhead box O (FoxO) and hypoxia-inducible factor-1α (HIF-1α)/vascular endothelial growth factor (VEGF) pathways and attenuated the activation of the mitogen-activated protein kinase (MAPK) signaling in OGD/R-treated cardiomyocytes. In conclusion, butorphanol prevents OGD/R-induced cardiomyocyte apoptosis through activating the PI3K/Akt/FoxO and HIF-1α/VEGF pathways and inactivating the MAPK pathway.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2021) studied Ischemic heart disease / OGD/R-induced cardiomyocyte apoptosis. Butorphanol vs. OGD/R alone was evaluated on Cardiomyocyte apoptosis and viability. Butorphanol protected human AC16 cardiomyocytes against OGD/R-induced apoptosis by activating the PI3K/Akt/FoxO and HIF-1α/VEGF pathways and inactivating the MAPK pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: